中国人兽共患病学报
中國人獸共患病學報
중국인수공환병학보
CHINESE JOURNAL OF ZOONOSES
2010年
2期
115-119
,共5页
闻慧琴%沈继龙%罗庆礼%李小月
聞慧琴%瀋繼龍%囉慶禮%李小月
문혜금%침계룡%라경례%리소월
芍药苷%日本血吸虫病%肝纤维化%胶原Ⅰ
芍藥苷%日本血吸蟲病%肝纖維化%膠原Ⅰ
작약감%일본혈흡충병%간섬유화%효원Ⅰ
paeoniflorin%Schistosoma japonicum%hepatic fibrosis%collagenⅠ
目的 探讨小鼠感染日本血吸虫后经吡喹酮治疗的不同时期,给予芍药苷对肝组织虫卵肉芽肿和纤维化的影响.方法 以日本血吸虫尾蚴感染BALB/c小鼠构建肝纤维化模型,随机分为(Ⅰ)杀虫前给药组、(Ⅱ)杀虫同时给药组及(Ⅲ)杀虫后给药组.除正常组外,杀虫治疗、芍药苷治疗组和对照组小鼠分别于感染后12d、42d和72d给予芍药苷和对照,并于102d、132d和162d处死.检测透明质酸(HA)、Ⅲ型前胶原氨基端肽(PⅢP)、羟脯氨酸(Hyp)、虫卵肉芽肿大小、肝纤维化分级以及胶原Ⅰ的表达.结果 在组Ⅰ和组Ⅲ,芍药苷明显降低血清中HA、PⅢP和肝组织中Hyp的含量,减小虫卵结节并降低肝纤维化严重程度分级,降低胶原Ⅰ的表达(P<0.05 或P<0.01);在组Ⅱ,大部分指标没有明显差别(P>0.05).结论 芍药苷无论是早期或延后给药,都具有抑制虫卵肉芽肿,减少胶原的生成从而对抗小鼠血吸虫性肝纤维化的作用.
目的 探討小鼠感染日本血吸蟲後經吡喹酮治療的不同時期,給予芍藥苷對肝組織蟲卵肉芽腫和纖維化的影響.方法 以日本血吸蟲尾蚴感染BALB/c小鼠構建肝纖維化模型,隨機分為(Ⅰ)殺蟲前給藥組、(Ⅱ)殺蟲同時給藥組及(Ⅲ)殺蟲後給藥組.除正常組外,殺蟲治療、芍藥苷治療組和對照組小鼠分彆于感染後12d、42d和72d給予芍藥苷和對照,併于102d、132d和162d處死.檢測透明質痠(HA)、Ⅲ型前膠原氨基耑肽(PⅢP)、羥脯氨痠(Hyp)、蟲卵肉芽腫大小、肝纖維化分級以及膠原Ⅰ的錶達.結果 在組Ⅰ和組Ⅲ,芍藥苷明顯降低血清中HA、PⅢP和肝組織中Hyp的含量,減小蟲卵結節併降低肝纖維化嚴重程度分級,降低膠原Ⅰ的錶達(P<0.05 或P<0.01);在組Ⅱ,大部分指標沒有明顯差彆(P>0.05).結論 芍藥苷無論是早期或延後給藥,都具有抑製蟲卵肉芽腫,減少膠原的生成從而對抗小鼠血吸蟲性肝纖維化的作用.
목적 탐토소서감염일본혈흡충후경필규동치료적불동시기,급여작약감대간조직충란육아종화섬유화적영향.방법 이일본혈흡충미유감염BALB/c소서구건간섬유화모형,수궤분위(Ⅰ)살충전급약조、(Ⅱ)살충동시급약조급(Ⅲ)살충후급약조.제정상조외,살충치료、작약감치료조화대조조소서분별우감염후12d、42d화72d급여작약감화대조,병우102d、132d화162d처사.검측투명질산(HA)、Ⅲ형전효원안기단태(PⅢP)、간포안산(Hyp)、충란육아종대소、간섬유화분급이급효원Ⅰ적표체.결과 재조Ⅰ화조Ⅲ,작약감명현강저혈청중HA、PⅢP화간조직중Hyp적함량,감소충란결절병강저간섬유화엄중정도분급,강저효원Ⅰ적표체(P<0.05 혹P<0.01);재조Ⅱ,대부분지표몰유명현차별(P>0.05).결론 작약감무론시조기혹연후급약,도구유억제충란육아종,감소효원적생성종이대항소서혈흡충성간섬유화적작용.
To probe the effect of paeoniflorin on periovular granuloma and liver fibrosis in mice infected with Schistosoma japonicum in different times of infection and the treatment with praziquantel (PZQ). The models of hepatic fibrosis induced by S.japonicum were established by exposure of BALB/c mice percutaneously through the tail to cercariae of S.japonicum. and mice with treatment were randomly divided into 3 groups: i.e. groups of pre-treatment (I), group of simultaneous treatment (Ⅱ) and group of post-treatment (III). All groups, except the normal control group, were orally introduced with PZQ. And mice in the paeoniflorin-treated group and control group were separately introduced with paeoniflorin and 0.5% sodium carboxymethycellulose respectively. The treatments in group I, II and III were started 30 days before PZQ usage, simultaneously with PZQ or 30days-after PZQ usage respectively. Mice in these groups were sacrificed on the 102, 132 or 162 days after infection. Then the serum levels of hyaluronic acid (HA), amino-terminal peptide of type III procollagen (PIIIP) and liver hydroxyproline (Hyp) were detected. The histopathology was examined by HE and Masson staining; the degree of hepatic fibrosis and the area of egg granuloma were analyzed. The expression of collagen I was examined by immunohistochemical method. It was found that the area of granuloma and degree of hepatic fibrosis in the paeoniflorin-treated groups in group I and III were significantly lower than those in the model control groups. Also, paeoniflorin could induce decreas expression of collagen I. Meanwhile the levels of serum HA, PIIIP and liver Hyp were all reduced in comparison with those in the control group (P<0.05 or P<0.01). However, in group Ⅱ, no significant difference was noted between the treated and the control group in most data. Paeoniflorin also showed the effects to reduce the size of periovular granuloma and to reduce the expression of type I collagen, thereby to resist the development of hepatic fibrosis caused by S. japonicum.-It is evident that PAE shows an efficaciously therapeutic effect on the development of liver fibrosis of shistosomiasis, whenever it is administered before or after the usage of schistosomicides.